Investing in new medical devices for future health landscapes


Future Cities Forum will be looking at the latest in medical technology innovations currently undergoing hospital trials across the UK and Europe, in our Science Cities forum at Cambridge on 20th November.

Recently the Office for Life Sciences issued its ninth annual update of its Strength and Opportunities report which gives a detailed picture of the size and shape of the life sciences industry in the UK. The report confirms that the UK remains a global hub for life sciences, with 5,469 life sciences business having a presence in the UK, generating £70 billion and employing nearly 241,000 people.

One of these SMEs, Lightpoint Medical, has developed a new device to aid the detection of cancerous tissue during head and neck cancer surgery. The firm is pleased to announce that its device called LightPath has now been installed at The Royal Marsden Hospital. The team at the hospital will be using LightPath in a new clinical study for cancer surgery.

Founded in 2012, Lightpoint Medical's aim is to become the world technology leader in targeted cancer surgery. The company's technology has the potential to detect cancer in real time during surgery, enabling surgeons to remove the cancerous tissue while sparing healthy tissue.

The technology is based on administering the patient a cancer-targeted imaging drug and then detecting the cancer live during surgery. Since the founding of the company, Lightpoint has achieved clinical trial data in multiple cancer types, regulatory clearance, and is well on its way to transforming the practice of cancer surgery.

E